Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Pharmacokinetics of Pilocarpine in Subjects with Varying Degrees of Renal Function

View through CrossRef
Data from three separate single‐center studies were combined to assess the pharmacokinetics of orally administered pilocarpine. Pilocarpine concentration‐time data were used to generate a data set including 42 subjects (34 males, 8 females) with varying degrees of renal function (average of two estimated creatinine clearance rates of 10 to 112 mL/min). Age ranged from 19 to 88 years. Subjects received single oral doses (range: 2.5–20 mg) of pilocarpine. Plasma samples were collected at time 0; at 20 and 40 minutes; and at 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours following dose administration. Cmax and AUC were normalized to a 5 mg exposure in those subjects who received doses other than 5 mg. Plasma pilocarpine concentrations were determined by gas chromatography/mass spectrometry. The pharmacokinetic parameters (elimination rate constant, Cmax, tmax, AUC, Vd/F, and Cl/F) in subjects with impaired renal function were similar to results found in other pharmacokinetic studies involving normal healthy volunteers with only Cmax being significantly higher (p < 0.05). No significant regression relationships were noted between creatinine clearance and pilocarpine elimination rate constant, tmax, Vd/F, Cl/F, or AUC. Pilocarpine clearance does not appear to be impaired in patients with varying degrees of renal insufficiency.
Title: Pharmacokinetics of Pilocarpine in Subjects with Varying Degrees of Renal Function
Description:
Data from three separate single‐center studies were combined to assess the pharmacokinetics of orally administered pilocarpine.
Pilocarpine concentration‐time data were used to generate a data set including 42 subjects (34 males, 8 females) with varying degrees of renal function (average of two estimated creatinine clearance rates of 10 to 112 mL/min).
Age ranged from 19 to 88 years.
Subjects received single oral doses (range: 2.
5–20 mg) of pilocarpine.
Plasma samples were collected at time 0; at 20 and 40 minutes; and at 1, 1.
5, 2, 3, 4, 6, 8, 12, 16, and 24 hours following dose administration.
Cmax and AUC were normalized to a 5 mg exposure in those subjects who received doses other than 5 mg.
Plasma pilocarpine concentrations were determined by gas chromatography/mass spectrometry.
The pharmacokinetic parameters (elimination rate constant, Cmax, tmax, AUC, Vd/F, and Cl/F) in subjects with impaired renal function were similar to results found in other pharmacokinetic studies involving normal healthy volunteers with only Cmax being significantly higher (p < 0.
05).
No significant regression relationships were noted between creatinine clearance and pilocarpine elimination rate constant, tmax, Vd/F, Cl/F, or AUC.
Pilocarpine clearance does not appear to be impaired in patients with varying degrees of renal insufficiency.

Related Results

Ictogenesis
Ictogenesis
*Michel Le Van Quyen, †Pascale Quilichini, †Yehezkel Ben‐Ari, †Christophe Bernard, and †Henri Gozlan ( *Neurodynamics Group, LENA‐CNRS UPR640, Hôpital de la Salpêtrière, Paris , an...
Anticonvulsive and Antioxidant Effects of Pioglitazone on Pilocarpine-induced Seizures in Mice
Anticonvulsive and Antioxidant Effects of Pioglitazone on Pilocarpine-induced Seizures in Mice
Background: Epilepsy is a neurological disorder caused by uncontrollable discharge of action potentials from neurons in the brain. After a seizure, oxidative stress may cause a sig...
Iridal posterior pigment epithelial detachment induced by pilocarpine: a case report
Iridal posterior pigment epithelial detachment induced by pilocarpine: a case report
Abstract Background Pilocarpine is a commonly used miotic agent in clinical ophthalmology and a first-line medication for glaucoma treatment. In recent years, it h...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
10th Annual Meeting, 25‐26 November 1976, Adelaide 1. Histamine metabolism in aortae of two histamine sensitive species. A. Foldes, M. J. Stacey and I. S. de la Lande 2. Localizat...
Muscarinic excitation of parvalbumin‐positive interneurons contributes to the severity of pilocarpine‐induced seizures
Muscarinic excitation of parvalbumin‐positive interneurons contributes to the severity of pilocarpine‐induced seizures
SummaryObjectiveA common rodent model in epilepsy research employs the muscarinic acetylcholine receptor (mAChR) agonist pilocarpine, yet the mechanisms underlying the induction of...
Pharmacological Evaluation of a New Timolol/Pilocarpine Formulation
Pharmacological Evaluation of a New Timolol/Pilocarpine Formulation
A new formulation (HYA) based on timolol hyaluronate and pilocarpine hyaluronate salts has been shown to improve the bioavailability of the drugs and to extend the duration of thei...

Back to Top